Tuoren Group has joined hands with Zhengzhou Zhongke Biology to tackle the "bottleneck" technologies in high-end medical devices

　　Recently, Tuoren Group and Zhengzhou Institute of Biomedical Engineering Technology of the Chinese Academy of Sciences (hereinafter referred to as Zhengzhou Institute of Biomedical Engineering Technology of the Chinese Academy of Sciences) officially signed a strategic cooperation agreement, injecting new impetus into the High-Performance Medical Device Innovation Consortium of Henan Province. This cooperation marks that both sides have entered a stage of in-depth collaboration in areas such as technological breakthroughs, technology transfer, and talent cultivation. Committed to building an innovation source of high-performance medical devices in China and promoting the high-quality development of the industry.

　　Wu Zaihui, Executive Vice President of Zhengzhou Zhongke Biological, and Wang Dong, Vice President; Wang Guosheng, the founder and president of Tuoren Group, Cheng Wensheng, the rotating president of the Medical group and the president of the Blue Light Laboratory, Cui Jingqiang, the vice president of the medical group and the director of the Zhengzhou R&D Center, and Shao Tianrui, the general manager of Zhengzhou Tuoren Medical Devices Co., LTD., attended the signing ceremony. Representatives from both sides had an in-depth exchange on the vision and strategic planning for cooperation.

　　Wang Guosheng emphasized in his speech that this cooperation will rely on the cutting-edge scientific research capabilities of Zhengzhou Zhongke Biology and the industrialization experience of Tuoren Group to connect the entire chain from "technology research and development - product transformation - clinical application", providing higher-quality solutions for the global medical market. Wu Zaihui stated that the research institute will fully leverage its cutting-edge technological advantages in the field of biomedical engineering and jointly break through key core technological bottlenecks with Tuoren Group. Through resource integration and collaborative innovation, we are expected to make a leap from "following" to "leading" in the high-end medical device field, and contribute to the national strategy of independent control of medical equipment.

　　The Henan Province High-Performance Medical Device Innovation Consortium is jointly established by hospitals, universities, research institutions and enterprises in the industrial chain. It aims to integrate resources from all parties, build an innovation center, academic center, transformation center and shared market in the field of high-end medical devices, and construct an international first-class "government-industry-university-research-medical" innovation ecosystem. Build a source of innovative brands for high-performance medical devices in China. The participation of Zhengzhou Zhongke Biology will further strengthen the basic research capabilities and original innovation advantages of the consortium, and accelerate the cultivation of a Chinese medical device brand with global competitiveness.

　　Zhengzhou Zhongke Biology mainly focuses on the high-end medical device field and is a provincial-level new research and development institution with the engineering and industrialization of medical devices as its main direction. As an innovative medical device enterprise, Tuoren Group has established a cooperative network with over 60 universities and accumulated rich industrialization experience. Both sides will take this cooperation as a new starting point, jointly build scientific research platforms, overcome technical difficulties, and cultivate professional talents to promote the localization process of high-end medical devices and provide solid technological support for the construction of a Healthy China.　　Source: Tuoren, Henan